Cohort characteristics. by Fernanda Talarico (807333)

Subjects:

Trend of mental health-related services utilization between 2016 and 2022. by Fernanda Talarico (807333)

Subjects:

Trend of all service utilization for all conditions between 2016 and 2022. by Fernanda Talarico (807333)

Subjects:

Probabilities of endorsing depressive symptoms derived from baseline 4-class latent class analysis (N = 619). by Carolin Oetzmann (11397968)

Subjects:

Model fit and class prevalence for baseline LCA models with varying numbers of classes and residual associations (N = 619). by Carolin Oetzmann (11397968)

Subjects:

Adjusted multinomial logistic regression models of class membership at baseline in relation to participant characteristics (N = 432). by Carolin Oetzmann (11397968)

Subjects:

Comparison of mental health-related services utilization between the pre (2016–2019) and post (2020–2022) pandemic onset periods. by Fernanda Talarico (807333)

Subjects:

Transition probabilities and class sizes for three-step LTA model (N = 432). by Carolin Oetzmann (11397968)

Subjects:

Characteristics of patients who decreased their screen time by more than 60 minutes after the challenge. by Annaëlle Le Steunf (19838110)

Presentation 1_Decreased brain-derived neurotrophic factor expression in chronic kidney disease: integrated clinical and experimental evidence.pptx by Juan Chen (61123)

“…</p>Conclusion<p>This study integrated meta-analysis, murine model validation, and single-cell transcriptomic profiling to demonstrate a significant reduction of BDNF in CKD. Furthermore, renal BDNF expression decreased locally, predominantly originating from proximal tubule cells, macrophages, and podocytes, possibly epigenetically inhibited by the upregulation of lnc RNA Bdnf-as.…”

Variations in the prevalence of OASI in France between 2010 and 2021 according to the classification for episiotomy practices. by Raphaele Houlbracq (20558509)

Subjects:

Trends in the characteristics of women giving birth vaginally in France between 2010 and 2021. by Raphaele Houlbracq (20558509)

Subjects:

Variations in the prevalence of episiotomy in France between 2010 and 2021 according to the classification for episiotomy practices. by Raphaele Houlbracq (20558509)

Subjects:

Flow chart. by Raphaele Houlbracq (20558509)

Subjects:

pmed.1004501.t001 - Episiotomies and obstetric anal sphincter injuries following a restrictive episiotomy policy in France: An analysis of the 2010, 2016, and 2021 National Perinat... by Raphaele Houlbracq (20558509)

Subjects:

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

<i>Aspergillus flavus</i> mRNA expression (a) <i>aflD</i> and (c) <i>aflR</i> and phylogenetic analysis of (b) <i>aflD</i> and (d) <i>aflR</i> after exposure to 50 mg/mL of <i>U. e... by Martha Cebile Jobe (21175426)

Subjects:

Everolimus decreased CD89 deposits in α1^KICD89^Tg mice. by Alexandra Cambier (22307216)